Tredup Claudia, Ackloo Suzanne, Beck Hartmut, Brown Peter J, Bullock Alex N, Ciulli Alessio, Dikic Ivan, Edfeldt Kristina, Edwards Aled M, Elkins Jonathan M, Farin Henner F, Fon Edward A, Gstaiger Matthias, Günther Judith, Gustavsson Anna-Lena, Häberle Sandra, Isigkeit Laura, Huber Kilian V M, Kotschy Andras, Krämer Oliver, Leach Andrew R, Marsden Brian D, Matsui Hisanori, Merk Daniel, Montel Florian, Mulder Monique P C, Müller Susanne, Owen Dafydd R, Proschak Ewgenij, Röhm Sandra, Stolz Alexandra, Sundström Michael, von Delft Frank, Willson Timothy M, Arrowsmith Cheryl H, Knapp Stefan
Institute of Pharmaceutical Chemistry, Goethe University Frankfurt Frankfurt 60438 Germany
Structural Genomics Consortium, BMLS, Goethe University Frankfurt Frankfurt 60438 Germany.
RSC Med Chem. 2024 Nov 29;16(2):457-464. doi: 10.1039/d4md00735b. eCollection 2025 Feb 19.
Target 2035 is a global initiative that seeks to identify a pharmacological modulator of most human proteins by the year 2035. As part of an ongoing series of annual updates of this initiative, we summarise here the efforts of the EUbOPEN project whose objectives and results are making a strong contribution to the goals of Target 2035. EUbOPEN is a public-private partnership with four pillars of activity: (1) chemogenomic library collections, (2) chemical probe discovery and technology development for hit-to-lead chemistry, (3) profiling of bioactive compounds in patient-derived disease assays, and (4) collection, storage and dissemination of project-wide data and reagents. The substantial outputs of this programme include a chemogenomic compound library covering one third of the druggable proteome, as well as 100 chemical probes, both profiled in patient derived assays, as well as hundreds of data sets deposited in existing public data repositories and a project-specific data resource for exploring EUbOPEN outputs.
“2035目标”是一项全球倡议，旨在到2035年识别出针对大多数人类蛋白质的药物调节剂。作为该倡议年度更新系列的一部分，我们在此总结欧盟开放药物研发平台（EUbOPEN）项目的工作，其目标和成果正在为“2035目标”的实现做出重大贡献。EUbOPEN是一个公私合作项目，有四个活动支柱：（1）化学基因组文库收集；（2）用于从苗头化合物到先导化合物转化的化学探针发现及技术开发；（3）在患者来源的疾病检测中对生物活性化合物进行分析；（4）项目范围内数据和试剂的收集、存储与传播。该项目的大量成果包括一个覆盖三分之一可成药蛋白质组的化学基因组化合物文库，以及100个化学探针，这些探针在患者来源的检测中均有分析，还有数百个数据集存入了现有的公共数据储存库，以及一个用于探索EUbOPEN成果的项目特定数据资源。
